Clinical scenarios addressing residual risk in ASCVD: Understanding the role of triglycerides and EPA

3 episodes

0.50 program credits

33m

ReachMD Healthcare Image

Details

Episodes

Documents

Presenters

Comments

Overview
Assessing residual risk is important for secondary prevention in patients with ASCVD. Elevated triglyceride levels are an independent maker of residual risk, even in patients with well-controlled LDL-c. The REDUCE-IT trial was designed to evaluate the effect of the omega-3 fatty acid icosapent ethyl in patients with high triglyceride levels and well-controlled LDL-c.
What are the outcomes of the REDUCE-IT trial and what do these results mean for clinical practice? Three experts share their insights on this topic.
Program Highlights
Understanding the role of triglycerides in the assessment of residual risk - Alberto Zambon - Padua, Italy
What is the pathophysiology of high triglyceride levels leading to progression of atherosclerosis? Alberto Zambon talks about potential pathways.
Managing a patient with residual risk: Applying recent evidence with EPA to practice - Kausik Ray - London, United Kingdom
The effect of omega-3FA on CV outcomes has been evaluated in many trials. Kausik Ray presents a meta-analysis of trials, and goes more in depth on those evaluating icosapent ethyl.
Integrating EPA in CV risk reduction strategies: Practical experience and guidance - Azfar Zaman - Newcastle, United Kingdom
How can icosapent ethyl be integrated in clinical practice? Azfar Zaman shares the essentials for incorporation of new treatments.
Instructions
- Watch the three lectures and answer the pre- and post-test questions
- Fill in the evaluation questions
- Download CME Certificate
For questions regarding this activity, please contact us at info@pace-cme.org.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Explain the relationship between triglycerides and cardiovascular outcomes
- Compare study results from trials with EPA vs the combination of EPA and DHA
- Describe the place of icosapent ethyl in ASCVD risk management
Target Audience
This is activity has been designed to meet the educational needs of cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with ASCVD.
Accreditation and Credit Designation Statements
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 36 minutes of effective education time.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credit(s)™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit(s)™.
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Commercial Support
Funding for this educational program was provided by an unrestricted educational grant from Amarin.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-CME.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 17/10/2024
Expiration Date: 17/10/2026

Understanding the Role of Triglycerides in the Assessment of Residual Risk.pdf

Managing a Patient with Residual Risk: Applying recent evidence with EPA to practice.pdf

Integrating Icosapent Ethyl in CV Risk Reduction Strategies: Practical Experience and Guidance.pdf

Prof. Alberto Zambon MD, PhD, FAHA

Prof. Alberto Zambon MD, PhD, FAHA

Kausik Ray, MBChB, MD, MPhil

Kausik Ray, MBChB, MD, MPhil

Azfar Zaman, MD

Azfar Zaman, MD